
Bionano Genomics (BNGO) Stock Forecast & Price Target
Bionano Genomics (BNGO) Analyst Ratings
Bulls say
Bionano Genomics demonstrated robust growth with a 17% increase in sales of nanochannel array flowcells in 2Q25, compared to the previous year, indicating heightened demand for its products. Additionally, the company reported an 11% year-over-year increase in combined revenue from consumables, software, and remaining services in 2Q25, driven by a notable 16% rise in consumables and software revenues. Furthermore, Bionano's expectations for new OGM installations for FY2025 have been raised to a range of 20-25, reflecting strong momentum and expanding utilization of its technology in emerging markets like Japan.
Bears say
Bionano Genomics faces significant risks that contribute to a negative outlook, including lower-than-expected market uptake and utilization of its products, which could hinder revenue growth. The company also struggles with potential difficulties in securing additional capital for operations, leading to dilution concerns for existing shareholders. Lastly, employing a conservative EV/Revenue multiple highlights the challenges in achieving favorable valuations amidst these operational uncertainties.
This aggregate rating is based on analysts' research of Bionano Genomics and is not a guaranteed prediction by Public.com or investment advice.
Bionano Genomics (BNGO) Analyst Forecast & Price Prediction
Start investing in Bionano Genomics (BNGO)
Order type
Buy in
Order amount
Est. shares
0 shares